Astria Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Astria Therapeutics
ATXS Stock  USD 12.58  0.08  0.64%   
Astria Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Astria Therapeutics' valuation are provided below:
Gross Profit
706 K
Market Capitalization
718.1 M
Enterprise Value Revenue
835.9621
Revenue
706 K
Earnings Share
(2.14)
There are over one hundred nineteen available fundamental signals for Astria Therapeutics, which can be analyzed over time and compared to other ratios. All traders should validate Astria Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 474.5 M in 2026. Enterprise Value is likely to gain to about 423 M in 2026
Check Astria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Astria Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 41 M, Selling And Marketing Expenses of 1.6 M or Other Operating Expenses of 134.7 M, as well as many indicators such as Price To Sales Ratio of 51.69, Dividend Yield of 0.0 or PTB Ratio of 1.72. Astria financial statements analysis is a perfect complement when working with Astria Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Astria Stock
Check out the analysis of Astria Therapeutics Correlation against competitors.
For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.

Astria Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets413.4 M393.7 M121.2 M
Slightly volatile
Other Current Liabilities16.2 M15.4 M5.3 M
Slightly volatile
Total Current Liabilities23.1 M22 M7.9 M
Slightly volatile
Property Plant And Equipment Net6.2 M5.9 M1.4 M
Slightly volatile
Accounts Payable5.2 M5 M1.6 M
Slightly volatile
Cash45.7 M68.8 M38.5 M
Slightly volatile
Non Current Assets Total9.3 M8.9 M2.4 M
Slightly volatile
Other Assets1.091.15279.4 K
Pretty Stable
Cash And Short Term Investments396.2 M377.4 M116.6 M
Slightly volatile
Common Stock Shares Outstanding67.8 M64.6 M14.7 M
Slightly volatile
Liabilities And Stockholders Equity413.4 M393.7 M121.2 M
Slightly volatile
Other Current Assets7.9 M7.5 M2.4 M
Slightly volatile
Total Liabilities16.6 M20.8 M18.1 M
Pretty Stable
Total Current Assets404.1 M384.8 M118.8 M
Slightly volatile
Common Stock68.8 K65.5 K21 K
Slightly volatile
Short and Long Term Debt Total2.6 M4.8 M3.6 M
Slightly volatile
Short Term Debt1.1 M1.2 M1.1 M
Very volatile
Other Liabilities58 K50.4 K71.3 K
Slightly volatile
Net Tangible Assets150.7 M143.5 M53 M
Slightly volatile
Current Deferred Revenue1.9 M2.2 M2.4 M
Slightly volatile
Common Stock Total Equity20 K32.2 K23.2 K
Pretty Stable
Net Invested Capital270.4 M257.5 M75.1 M
Slightly volatile
Property Plant And Equipment Gross6.2 M5.9 M1.5 M
Slightly volatile
Short and Long Term Debt2 M2.2 M2.4 M
Slightly volatile
Net Working Capital381 M362.8 M108.2 M
Slightly volatile
Property Plant Equipment796.5 K853.2 K771.7 K
Slightly volatile
Capital Stock60.3 M109.7 M32.6 M
Slightly volatile
Non Current Liabilities Other222.2 K410.6 K188.1 K
Slightly volatile
Capital Lease Obligations6.5 M6.2 M2.5 M
Slightly volatile
Capital Surpluse506 M569.3 M621.4 M
Slightly volatile
Preferred Stock Total Equity77.1 M86.8 M94.7 M
Slightly volatile

Astria Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative41 M39 M14.2 M
Slightly volatile
Selling And Marketing Expenses1.6 M1.5 M598.1 K
Slightly volatile
Other Operating Expenses134.7 M128.3 M54.8 M
Slightly volatile
Research Development93.1 M88.7 M30.8 M
Slightly volatile
Total Operating Expenses134.7 M128.3 M54.8 M
Slightly volatile
Cost Of Revenue22.2 K23.4 K120.4 K
Slightly volatile
Interest Income21 M20 M4.3 M
Slightly volatile
Reconciled Depreciation22.2 K23.4 K161.9 K
Slightly volatile
Non Operating Income Net Other1.3 M1.5 M1.6 M
Slightly volatile

Astria Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation15.7 M15 M4.1 M
Slightly volatile
Begin Period Cash Flow212.1 M202 M53 M
Slightly volatile
Depreciation22.2 K23.4 K105.3 K
Slightly volatile
Capital Expenditures307.1 K292.5 K137.3 K
Slightly volatile
Total Cash From Financing Activities189.8 M180.8 M65.6 M
Slightly volatile
End Period Cash Flow45.8 M68.8 M38.6 M
Slightly volatile
Change To Netincome5.1 M5.4 M12.6 M
Pretty Stable
Issuance Of Capital Stock94.7 M175.3 M73.5 M
Slightly volatile
Dividends Paid19.5 M22 M24 M
Slightly volatile
Sale Purchase Of Stock86.2 M97 M105.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio51.6958.1563.4707
Slightly volatile
Stock Based Compensation To Revenue3.213.613.9429
Slightly volatile
Capex To Depreciation0.860.530.7118
Slightly volatile
EV To Sales29.4633.1536.1807
Slightly volatile
Payables Turnover0.190.09720.1269
Slightly volatile
Sales General And Administrative To Revenue14.2616.0417.5094
Slightly volatile
Research And Ddevelopement To Revenue29.8933.6336.7047
Slightly volatile
Capex To Revenue0.0880.10.1116
Slightly volatile
Cash Per Share6.386.7264.952
Slightly volatile
Days Payables Outstanding2.1 K3.9 K3.3 K
Slightly volatile
Income Quality0.950.990.8911
Pretty Stable
Net Debt To EBITDA0.750.440.7901
Pretty Stable
Current Ratio8.9815.7410.3832
Slightly volatile
Capex Per Share0.00630.00670.4086
Slightly volatile
Revenue Per Share1.11.251.3591
Slightly volatile
Interest Debt Per Share0.10.1116.4727
Slightly volatile
Debt To Assets0.01710.0180.1233
Slightly volatile
Days Of Payables Outstanding2.1 K3.9 K3.3 K
Slightly volatile
Ebt Per Ebit1.080.970.9854
Slightly volatile
Quick Ratio8.9815.7410.3832
Slightly volatile
Cash Ratio4.742.815.3173
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.151.0224
Slightly volatile
Fixed Asset Turnover1.251.41.5303
Slightly volatile
Debt Ratio0.01710.0180.1233
Slightly volatile
Price Sales Ratio51.6958.1563.4707
Slightly volatile
Asset Turnover0.02230.02510.0274
Slightly volatile

Astria Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap474.5 M451.9 M164.6 M
Slightly volatile

Astria Fundamental Market Drivers

Astria Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Astria Therapeutics Financial Statements

Astria Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Astria Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Astria Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Astria Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.2 M1.9 M
Cost Of Revenue23.4 K22.2 K
Stock Based Compensation To Revenue 3.61  3.21 
Sales General And Administrative To Revenue 16.04  14.26 
Research And Ddevelopement To Revenue 33.63  29.89 
Capex To Revenue 0.10  0.09 
Revenue Per Share 1.25  1.10 
Ebit Per Revenue(48.77)(51.21)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Astria Stock Analysis

When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY